Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 297 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: CMV Clear all
Completed Not applicable Interventional

An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS

NCT00002142
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Cidofovir, Probenecid
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus

NCT00880789
View directory record Official record
Conditions
Cytomegalovirus Infection, Adenovirus Infection
Interventions
CMV/AdV specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Jul 22, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females

NCT00133497
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
MF-59, Placebo, CMV gB vaccine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 17 Years · Female only
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
5
States / cities
Cincinnati, Ohio • Nashville, Tennessee • Galveston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Jul 22, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

NCT04017962
View directory record Official record
Conditions
CMV, CMV Infection, Hematopoietic Cell Transplant
Interventions
Letermovir Pill, blood draw
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jul 22, 2026, 5:49 PM EDT
Active, not recruiting Phase 3 Interventional

De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients

NCT06001320
View directory record Official record
Conditions
Kidney Transplant; Complications, CMV
Interventions
Letermovir 480 mg once daily, Historical/Control
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 5:49 PM EDT
Completed Phase 3 Interventional

A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients

NCT00001038
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Valacyclovir hydrochloride, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Jul 22, 2026, 5:49 PM EDT
Not listed Phase 1 Interventional

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

NCT00769613
View directory record Official record
Conditions
Cancer
Interventions
cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes, polymerase chain reaction, flow cytometry, immunological diagnostic method, laboratory biomarker analysis
Biological · Genetic · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jul 22, 2026, 5:49 PM EDT
Completed Phase 4 Interventional

A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)

NCT00002125
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Beverly Hills, California • Los Angeles, California • Redwood City, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)

NCT01376778
View directory record Official record
Conditions
Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection
Interventions
CMV hyperimmune globulin, Placebo
Drug · Other
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
399 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Jul 22, 2026, 5:49 PM EDT
Recruiting Phase 2 Interventional

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

NCT06066957
View directory record Official record
Conditions
Cytomegalovirus Infections, Transplant-Related Disorder
Interventions
Letermovir 480 MG [Prevymis]
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 22, 2026, 5:49 PM EDT
Active, not recruiting Phase 2 Interventional

Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection

NCT02210078
View directory record Official record
Conditions
Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 22, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)

NCT01070797
View directory record Official record
Conditions
Adenovirus Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections, Stem Cell Transplant
Interventions
Multi-virus Specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Jul 22, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

NCT00533923
View directory record Official record
Conditions
AML, ALL, CLL, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Aplastic Anemia, Myeloproliferative Disorder
Interventions
Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Up to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Jul 22, 2026, 5:49 PM EDT
Completed No phase listed Observational

A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients.

NCT00273143
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Jul 22, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

NCT04232280
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
mRNA-1647, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
9
States / cities
Sacramento, California • Peoria, Illinois • Lenexa, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 22, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis

NCT00002321
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 5:49 PM EDT
Completed Not applicable Interventional Results available

Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant

NCT02108522
View directory record Official record
Conditions
Infection
Interventions
Multivirus Specific T cells
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Jul 22, 2026, 5:49 PM EDT
Terminated Phase 1 Interventional

CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease

NCT00611637
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation
Interventions
CMV pp65 Specific T Cells
Biological
Lead sponsor
H. Kim Lyerly
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 11, 2012 · Synced Jul 22, 2026, 5:49 PM EDT
Completed Phase 1Phase 2 Interventional

Valganciclovir in Congenital CMV Infants

NCT00031434
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
Valganciclovir, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 30 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2011 · Synced Jul 22, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

NCT01877655
View directory record Official record
Conditions
Cytomegalovirus (CMV)-Positive Recipients, Allogeneic, Hematopoietic Cell Transplant (HCT)
Interventions
ASP0113, Placebo
Biological · Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Jul 22, 2026, 5:49 PM EDT
Completed No phase listed Observational

CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients

NCT03924219
View directory record Official record
Conditions
Heart Transplant Infection, Kidney Transplant Infection, Liver Transplant Infection, CMV
Interventions
CMV T cell Immunity Assay
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
0 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
12
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 22, 2026, 5:49 PM EDT
Active, not recruiting Phase 2 Interventional

Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants

NCT03107871
View directory record Official record
Conditions
Cmv Congenital, CMV, Congenital Cmv, SNHL, Sensorineural Hearing Loss
Interventions
Valganciclovir, Simple Syrup
Drug
Lead sponsor
Albert Park
Other
Eligibility
1 Month to 12 Months
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Jul 22, 2026, 5:49 PM EDT
Completed No phase listed Observational Results available

Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Receiving Treatment for Cytomegalorivus (CMV) Infection

NCT01602614
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 180 Days
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Jul 22, 2026, 5:49 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant

NCT03570411
View directory record Official record
Conditions
CMV
Interventions
T-SPOT®.CMV Test
Diagnostic Test
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Jul 22, 2026, 5:49 PM EDT